bet 747
Bitcoin topped US$100,000 for the first time on Dec 5, jumping drastically from roughly $69,000 the day before the US presidential election about a month earlier. The sharp uptick in price has prompted investors, particularly cryptocurrency enthusiasts, to keep a close eye on what happens next in US politics. As a candidate, Donald Trump pledged to make the US the "crypto capital of the planet". Now the president-elect even suggested the country might one day pay off its national debt in cryptocurrency. "During the campaign, Trump promised many policy changes in the US that will be favourable for Bitcoin and crypto assets in general. We have already seen the impact of this, driving Bitcoin prices to all-time highs," said Nirun Fuwattananukul, chief executive of Gulf Binance, the Thai joint venture between the world's largest crypto exchange and SET-listed Gulf Energy Development. In Mr Nirun's view, these policies are likely to be pushed through. Trump's second term, unlike his first, will have a Republican majority in the Senate and House of Representatives. "This means he can drive his campaign policy very effectively. His campaign advisors, especially Elon Musk and Robert F. Kennedy Jr, are also very pro-Bitcoin, so I think these pledged policies will be implemented," he told the Bangkok Post. CRYPTO BOOST Mr Nirun said before the US election, Bitcoin was already a well-known and widely adopted asset globally. In the US, many institutions and state pension funds are starting to invest in the world's largest cryptocurrency. "New regulations, if they happen, will make Bitcoin even more mainstream. I believe Bitcoin will become a mainstream investment asset, similar to gold or silver, in the future," he said. Mr Nirun said the general cryptocurrency market will likely follow Bitcoin, with more assets becoming mainstream, taking the Ethereum path. "I think the key driver will be greater innovation. With supportive US policy and more capital returning to the US, we will see more innovation in this space, with new applications and use cases driving crypto assets to become more mainstream in the future," he said. The market anticipates Gary Gensler, chair of the US Securities and Exchange Commission (SEC), leaving his post at the end of Joe Biden's administration. Investors are optimistic about a more crypto-friendly regulator after his departure in early 2025. "He was very active in regulatory enforcement on Bitcoin and crypto assets. The new SEC chairman will likely be much more aligned with Trump's views," said Mr Nirun. Last Wednesday, Trump announced he intends to nominate cryptocurrency advocate Paul Atkins to chair the SEC. Mr Atkins, the chief executive of Patomak Partners and a former SEC commissioner, has made the case against too much market regulation since he left the US stock market regulator. However, realising the benefits of favourable crypto policies of the new US administration will take time, said Mr Nirun. "I think we need to wait for the proper timing. There are a lot of pressing issues Americans expect Trump to tackle, including the economy and immigration, which will likely come first. We need to wait a bit to see when he will start looking into Bitcoin and crypto assets," he said. "The devil is in the details. Crypto is a complex issue and drafting a new law for this will take time." The FIT21 bill, a comprehensive regulatory framework for digital assets, was previously passed by the House and is now waiting in the Senate. "If Trump wants to redraft the entire bill, this will take even more time," said Mr Nirun. "Hopefully the next SEC chairman is someone with a strategic vision for crypto in the long term." Binance co-founder Yi He shared a similar view, saying products such as spot Bitcoin and Ethereum exchange-traded funds have broadened the industry's circle, and these increasing overlaps and innovations indicate a good year is ahead. STABLECOIN OPTIMISM Jeremy Allaire, chief executive of Circle, the issuer of the second-largest stablecoin, expressed optimism regarding global regulation of the sector. He believes the next 10-12 months will be crucial for the stablecoin space, which has already grown to roughly $170 billion, with Tether's USDT and Circle's USDC responsible for the lion's share. However, this is a fraction of the global financial space and the $130-trillion global electronic money market. This means the stablecoin industry still has huge potential for growth, said Mr Allaire. A type of cryptocurrency that aims to maintain a fixed value relative to another asset or currency, stablecoins are often pegged to a traditional currency, namely the US dollar or the euro, or other assets such as gold or silver. "The next 12 months is a pretty big inflection point for stablecoins," he said, with regulatory frameworks in some key jurisdictions expected to take shape over the next year. Speaking at Binance Blockchain Week in Dubai, Mr Allaire likened these early days of digital currency to the early days of digital media, explaining how lowering communication costs spurred rapid growth and revolutionised industries. He suggested achieving similar advancements in transaction costs with programmable money could fundamentally reshape the ways we transfer and manage value in the financial landscape. USDC, Circle's stablecoin, has increasingly been adopted across financial and payment networks, suggesting stablecoins are poised to become a foundational layer in the digital economy, with real-world applications expanding from here, said Mr Allaire. In terms of regulation, he was cautiously optimistic, noting the regulatory environment in several countries had positive sentiment for stablecoins. While a certain level of regulatory hurdles remains, a shift in attitudes among policymakers is taking place, particularly in the US, which is now recognising the long-term value that digital assets can bring, said Mr Allaire. In fact, even those voicing public opposition to the sector or sitting on the sidelines are watching the vanguard, ready to follow suit with comprehensive regulations, he said. This openness can pave the way for a balanced approach that supports innovation without stifling progress, said Mr Allaire. REGULATORY COMPLIANCE Ms Yi acknowledged the past year posed significant challenges, even for industry leaders such as Binance, to sustain growth momentum. With more than 200 million users globally, the world's largest crypto exchange remains focused on building a brighter future for the sector and increasing financial accessibility, she said. Navigating industry-wide regulatory and compliance challenges is an ongoing priority for Binance. While such challenges are complex, Binance views them as necessary for long-term growth and trust within the ecosystem, said Ms Yi. Collaboration with regulators is crucial to achieving mass adoption. "If we want a billion users of crypto, we must cooperate with the regulators. That's how we become the next Google or Amazon of crypto," she said. Access is essential to Binance, as Ms Yi hopes her grandmother or a nanny can easily open the Binance app and use crypto. Noah Perlman, chief compliance officer of Binance, said as more of the world transitions from traditional finance to blockchain, global regulations and compliance is becoming more important than ever. "We can all agree that 2023 was the year in which regulators and policymakers really stepped up their efforts to develop frameworks for the industry," he said. "It is very difficult to follow the rules if they are constantly changing." Having regulations that are difficult to follow or deny product users what they want inevitably pushes users to unregulated spaces, said Mr Perlman, who has a background in traditional finance, adding regulatory frameworks offer certainty, which markets crave. "As we get more certainty in the market through policies such as MiCA, it is going to encourage more people to enter the space," he said, referring to the Markets in Crypto-Assets Regulation that came into force in June 2023. Yuelin Li, chief product officer of tech startup Onfido, said a clear regulatory framework provides "a sense of safety for consumers", which is the defining factor between those who are willing to give crypto a shot and those who prefer to stay within the realms of traditional finance. Bora Erdamar, director of BlockchainIST Center, an R&D centre for blockchain technology, said the roles of project developers and experts help to bridge the gap between the crypto ecosystem and conventional finance. "We need to make it easier to understand and use blockchain," he said. 2025 TRENDS Alex Svanevik, chief executive of leading on-chain analytics platform Nansen, believes 2025 will see the "biggest bull run in history", supported by Trump's victory in the US election. For next year, meme coins -- cryptocurrencies inspired by internet memes -- will continue to attract retail investors to the crypto space. He anticipates these tokens will significantly boost on-chain metrics, leading to unprecedented records in decentralised exchange (DEX) volumes across multiple blockchain networks. "Meme coins continue to onboard retail to crypto and smash on-chain metrics. We'll see new records in DEX volume for lots of chains," he said. "Better infrastructure, easier user experience, lower transaction fees -- all these make the journey on-chain better for newcomers." Mr Svanevik also foresees a resurgence in decentralised finance (DeFi), driven by clearer regulations and the activation of revenue models within DeFi protocols. With the departure of Mr Gensler from the SEC on Jan 20, he predicts regulatory hurdles will be reduced and institutional capital will flow more freely into DeFi platforms. Mr Svanevik said he envisions cryptocurrencies playing a dual role in accelerating artificial intelligence (AI) projects and offering solutions to mitigate associated risks. "Crypto accelerates AI, but also protects us from AI," he said, adding crypto dollars should continue to pour into AI projects. Binance chief executive Richard Teng said the future is bright for crypto. "We are on the path of mass adoption because every major global financial institution is either embracing crypto or pushing ahead with the blockchain agenda," he said.‘It’s not a death sentence’: How mum of two overcomes stage 4 lung cancer and finds calling in comforting others
Security beefed up in Panipat for PM Modi’s visit todayAssam: BJP wrests Congress-stronghold Samaguri in bypollA PREMIER League star’s domestic rubbish was dumped illegally outside an apartment block. Furious residents contacted Crystal Palace to report Jefferson Lerma for fly-tipping . The club investigated and discovered that the Colombian midfielder, 30, had paid for a “legitimate waste disposal service” to dispose of the trash “in good faith”. The rubbish was strewn across the front of garages behind flats in Streatham, South London — nine miles from Lerma’s home. Grainy CCTV images show men arriving in cars with fake number plates to dump the trash. The garbage included broken toys, full carrier bags and dozens of opened parcels and boxes bearing Lerma’s address. READ MORE FOOTBALL NEWS Recent windy weather spread the rubbish further. Heidi Vella, who lives in the flats, said: “Fly-tipping is illegal and a social blight and so it was a real shock to the residents here to see a Premier League footballer’s rubbish dumped on our property. “A quick look showed it was Jefferson Lerma’s domestic rubbish. Now we want to pursue the ‘man with a van’ so he is dealt with by law.” Lerma signed for Bournemouth for £25million in 2018 and joined Palace on a free transfer last year. Most read in Football The club said: “When this matter was drawn to our attention, we immediately arranged for the rubbish to be collected and disposed of correctly. “We apologise for any inconvenience.”
Miami aims to halt skid in encounter vs. VCU
A PREMIER League star’s domestic rubbish was dumped illegally outside an apartment block. Furious residents contacted Crystal Palace to report Jefferson Lerma for fly-tipping . 3 Crystal Palace's Jefferson Lerma has been reported for fly-tipping Credit: Getty 3 The garbage included broken toys, full carrier bags and dozens of opened parcels and boxes bearing Lerma’s address The club investigated and discovered that the Colombian midfielder, 30, had paid for a “legitimate waste disposal service” to dispose of the trash “in good faith”. The rubbish was strewn across the front of garages behind flats in Streatham, South London — nine miles from Lerma’s home. Grainy CCTV images show men arriving in cars with fake number plates to dump the trash. The garbage included broken toys, full carrier bags and dozens of opened parcels and boxes bearing Lerma’s address. READ MORE FOOTBALL NEWS money talks Football icon turned down big money I’m A Celeb offer - but there's a twist KICKING OFF Footie ultras ARRANGING Fight Club-style brawls with brutal rules of engagement Recent windy weather spread the rubbish further. Heidi Vella, who lives in the flats, said: “Fly-tipping is illegal and a social blight and so it was a real shock to the residents here to see a Premier League footballer’s rubbish dumped on our property. “A quick look showed it was Jefferson Lerma’s domestic rubbish. Now we want to pursue the ‘man with a van’ so he is dealt with by law.” Lerma signed for Bournemouth for £25million in 2018 and joined Palace on a free transfer last year. Most read in Football LEVEL HEAD Clement shrugs off Celtic record as Rangers boss warns against Hoops' mind games BOOKIE BASHER Jim Delahunt's Celtic v Rangers League Cup Final verdict & 12/1 weekend acca LEAVE IT OUT Rodgers makes something clear about Clement 'financially out our league' claim CRYSTAL BALL Celtic vs Rangers score predictions as SunSport writers have their say The club said: “When this matter was drawn to our attention, we immediately arranged for the rubbish to be collected and disposed of correctly. “We apologise for any inconvenience.” Bournemouth target Jefferson Lerma is an absolute beast of a defensive midfielder 3 Heidi Vella, who lives in the flats, said: 'Fly-tipping is illegal and a social blight and so it was a real shock to the residents here to see a Premier League footballer’s rubbish dumped on our property' Credit: Louis Wood
KBC Group NV Boosts Position in Albany International Corp. (NYSE:AIN)Pair of wins, including thriller in semifinals, put Boise State in Caymans title game
New York, USA, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Neuroendocrine Tumors Market to Showcase Rapid Growth During the Study Period (2020–2034), at a CAGR of 5.1%| DelveInsight The launch of upcoming therapies such as ITM-11, CAM2029, RYZ101, CABOMETYX, ALPHAMEDIX, and others in the forecast period, rising incident population due to an increased number of endoscopic and radio-imaging studies, increasing research activities are driving neuroendocrine tumor market size. Companies such as Novartis, ITM Solucin GMBH, Camurus, Bristol Myers Squibb, Rayzebio, Exelixis, Ipsen, Takeda, and others are competing fiercely to capture the largest market sizes. DelveInsight’s latest Neuroendocrine Tumors Market Insights report includes a comprehensive understanding of current treatment practices, emerging neuroendocrine tumor drugs, market share of individual therapies, and current and forecasted neuroendocrine tumors market size from 2020 to 2034, segmented into 6MM [the United States, the EU4 (Germany, France, Italy, and Spain), and the United Kingdom]. Key Takeaways from the Neuroendocrine Tumors Market Report According to DelveInsight’s analysis, the market size of neuroendocrine tumors in the US was USD 1.5 billion in 2023. In 2023, Somatostatin analogs (SSAs) captured the highest market size of approximately USD 700 million in the US, followed by LUTATHERA . However, by 2034, radioligand treatments including approved beta emitter-radioligand therapy [LUTATHERA], and most anticipated alpha emitter-based therapies are expected to drive the overall NETs market size. The total number of incident cases of NETs in the US was nearly 29,500 cases in 2023 and is projected to increase by 2034. Prominent emerging companies working in the domain of neuroendocrine tumors, including ITM Solucin GMBH , Camurus , Bristol Myers Squibb , Rayzebio , Exelixis , Ipsen , Takeda , Radiomedix , Orano Med , Perspective Therapeutics , Elicera Therapeutics , Chimerix , Enterome , Teclison , and others, are actively working on innovative neuroendocrine tumor drugs. These novel neuroendocrine tumor therapies are anticipated to enter the neuroendocrine tumors market in the forecast period and are expected to change the market. Some of the key emerging neuroendocrine tumor treatments include ITM-11 (N.C.A. 177LU-EDOTREOTIDE), CAM2029, RYZ101 (ACTINIUM-225 DOTATATE), CABOMETYX (Cabozantinib), ALPHAMEDIX (212PB-DOTAMTATE), [212PB] VMT- -NET , ELC-100 (ADVINCE), ONC201 , EO2401 + NIVOLUMAB , TIRAPAZAMINE (TEC-001) , and others. As the field of radioligand therapy evolves, there is an exciting shift towards alpha-emitting radioisotopes. At present, only beta-emitting radioisotopes are currently approved, companies are now focusing on developing alpha-emitters. In August 2024, Exelixis announced that its supplemental New Drug Application (sNDA) for CABOMETYX has been accepted in the US for: 1) the treatment of adults with previously treated, locally advanced/unresectable or metastatic, well- or moderately differentiated pancreatic neuroendocrine tumors (pNET), and 2) the treatment of adults with previously treated, locally advanced/unresectable or metastatic, well- or moderately differentiated extra-pancreatic NET (epNET). The US Food and Drug Administration (FDA) assigned a standard review with a Prescription Drug User Fee Act (PDUFA) target action date of April 3, 2025. In July 2024 , Curium announced that it had submitted its 505(b)(2) NDA for Lutetium Lu 177 Dotatate Injection for the treatment of somatostatin receptor-positive (SSTR+) GEP-NETS. In April 2024, Novartis announced that the US FDA approved LUTATHERA for the treatment of pediatric patients 12 years and older with SSTR+ GEP-NETs, including foregut, midgut, and hindgut NETs. Discover which therapies are expected to grab the NETs market share @ Neuroendocrine Tumors Market Report Neuroendocrine Tumors Overview Neuroendocrine Tumors (NETs) are a diverse group of cancers that arise from neuroendocrine cells, which have characteristics of both nerve cells and hormone-producing cells. These tumors can develop anywhere in the body but are most commonly found in the gastrointestinal tract, pancreas, and lungs. The exact causes of neuroendocrine tumors are not fully understood, but certain factors may increase risk, including genetic syndromes like multiple endocrine neoplasia type 1 (MEN1), Von Hippel-Lindau disease, and neurofibromatosis. Other potential contributors include chronic inflammatory conditions, smoking, and exposure to certain chemicals. Symptoms of NETs can vary widely depending on the tumor's location and whether it secretes hormones. Some tumors may be asymptomatic for a long time. Common symptoms include abdominal pain, diarrhea, flushing of the skin, unexplained weight loss, and in cases of hormone-secreting tumors, symptoms related to excess hormones, such as changes in blood sugar levels or high blood pressure. Diagnosing NETs typically involves a combination of blood and urine tests to detect hormone levels, imaging studies like CT, MRI, or PET scans, and biopsies to analyze tumor tissue. Specialized tests like chromogranin A (CgA) blood tests or somatostatin receptor scintigraphy (Octreoscan) may also be used to identify neuroendocrine activity and locate tumors. Neuroendocrine Tumors Epidemiology Segmentation The neuroendocrine tumors epidemiology section provides insights into the historical and current neuroendocrine tumors patient pool and forecasted trends for the 6MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The neuroendocrine tumors market report proffers epidemiological analysis for the study period 2020–2034 in the 6MM segmented into: Total Incident Cases of NET Cases of NETs by Grade Stage-specific Cases of NET Cases of NETs by Site Cases of NETs by Functional Status Download the report to understand which factors are driving NETs epidemiology trends @ Neuroendocrine Tumors Epidemiological Insights Neuroendocrine Tumors Treatment Market Surgery is generally considered a first-line treatment for localized NETs. The frontline treatment for metastatic disease is somatostatin analogs, and currently, two agents are FDA-approved: SANDOSTATIN (octreotide acetate) and SOMATULINE DEPOT (lanreotide). Both somatostatin analogs provide symptomatic relief in 50% to 70% of patients and biochemical responses in 40% to 60% of patients. Traditionally, mTOR inhibitor – everolimus or sunitinib – was acknowledged as a second-line agent, but with the recent approval of PRRT (peptide receptor radionuclide therapy), the choice of second-line therapy is debatable. While GEP-NETs in children and adolescents are rare, the impact can be devastating. Advanced Accelerator Applications (AAA)/Novartis’s LUTATHERA is now the very first therapy approved specifically for use in pediatric patients with GEP-NETs. offering new hope to young patients living with this rare cancer. In January 2018, the FDA approved LUTATHERA, a radiolabeled somatostatin analog for the treatment of GEP-NETs. In April 2024, Novartis announced that the US FDA approved LUTATHERA for the treatment of pediatric patients 12 years and older with SSTR+ GEP-NETs, including foregut, midgut, and hindgut NETs. LUTATHERA is also approved in Europe for unresectable or metastatic, progressive, well-differentiated (G1 and G2), SSTR-positive GEP-NETs in adults, and in Japan for SSTR-positive NETs. All available therapies for NETs, whether monotherapy or combination, are currently leveraged to treat this complex, diverse population of patients, yet no treatment has maintained progression-free survival (PFS) indefinitely. At present, the NETs market is dominated by SSAs, however, by 2034, radioligand therapies are projected to capture the highest market share, reflecting a paradigm shift driven by their enhanced efficacy and the growing adoption of targeted treatment approaches. While LUTATHERA has primarily been used as a second-line treatment, there is a growing interest in expanding its use to first-line settings for medium- and high-risk NETs. This trend underscores the rising prominence of radioligand therapies in redefining treatment standards in the NETs space. Learn more about the market of NETs @ Neuroendocrine Tumors Treatment Neuroendocrine Tumors Emerging Drugs and Companies Some of the drugs in the pipeline include ITM-11 (ITM Isotope Technologies Munich), CABOMETYX (Exelixis/Ipsen/Takeda), CAM2029 (Camurus), AlphaMedix (Radiomedix/Orano Med), VMT- -NET (Perspective Therapeutics), and others. CABOMETYX (cabozantinib) is a small-molecule inhibitor targeting several receptor tyrosine kinases, such as VEGFRs, MET, RET, and the TAM family (TYRO3, MER, AXL). In August 2024, the FDA accepted a supplemental New Drug Application (sNDA) for cabozantinib to treat patients with advanced pancreatic neuroendocrine tumors (pNET) and extra-pancreatic neuroendocrine tumors (epNET) who have previously undergone treatment. The FDA set a PDUFA target date of April 3, 2025, for review and granted orphan drug designation for pNET. This application is supported by data from the Phase III CABINET trial, which studied CABOMETYX in these patient populations. ITM-11 (177Lu-edotreotide) , developed by ITM Isotope Technologies Munich , is a novel Targeted Radionuclide Therapy that combines two components: Edotreotide (DOTATOC), an octreotide-based somatostatin analog, and EndolucinBeta (n.c.a. lutetium-177 chloride), a low-energy beta-emitting synthetic radioisotope. It is currently under investigation in two Phase III clinical trials: COMPETE (NCT03049189) and COMPOSE (NCT04919226). COMPETE focuses on assessing ITM-11 for treating Grade 1 and Grade 2 GEP-NETs, while COMPOSE investigates its use in patients with well-differentiated high Grade 2 and Grade 3 GEP-NETs. ITM-11 was granted orphan designation for GEP-NET treatment based on Phase II data showing significant improvement in PFS. The other pipeline therapies for neuroendocrine tumors include RYZ101 (ACTINIUM-225 DOTATATE): BRISTOL MYERS SQUIBB/RAYZEBIO CAM2029: Camurus ALPHAMEDIX (212PB-DOTAMTATE): RADIOMEDIX/ORANO MED [212PB] VMT-α-NET: PERSPECTIVE THERAPEUTICS ELC-100 (ADVINCE): ELICERA THERAPEUTICS ONC201: CHIMERIX EO2401 + NIVOLUMAB: ENTEROME TIRAPAZAMINE (TEC-001): TECLISON It is more important than ever to ensure and understand supply chain and manufacturing issues of radiopharmaceuticals to stay at the forefront of radiopharmaceutical innovation, especially since a number of companies are investigating radiopharmaceuticals. Emerging key players should make sure that their product, supply, and production capabilities are adequate, and they should be prepared to meet the challenge of offering new therapeutic approaches to cancer patients who otherwise have limited options. In June 2024, BMS-RayzeBio was forced to pause a phase III trial due to an actinium shortage. Oncolytic virotherapy holds promise for cancer treatment. Oncolytic virotherapies like ELC100 (Elicera Therapeutics) and SVV-001 (Seneca therapeutics) are also being investigated for the treatment of NETs in early clinical trials. The anticipated launch of these emerging therapies are poised to transform the neuroendocrine tumors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the neuroendocrine tumors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about NETs clinical trials, visit @ Neuroendocrine Tumors Treatment Drugs Neuroendocrine Tumors Market Dynamics The neuroendocrine tumors market dynamics are anticipated to change in the coming years. NETs are often diagnosed at an early stage due to the hormonal symptoms they produce, allowing for timely intervention and better outcomes, and with advancements like LUTATHERA being the first therapy specifically approved for pediatric patients with GEP-NETs, along with continued research in targeted therapies such as somatostatin analogs and molecular inhibitors, there are growing opportunities for more effective and personalized treatments ; participation in clinical trials can further drive the discovery of new treatment modalities and improve patient outcomes. Furthermore, many potential therapies are being investigated for the treatment of NETs, and it is safe to predict that the treatment space will significantly impact the NETs market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the NETs market in the 6MM. However, several factors may impede the growth of the neuroendocrine tumors market. Since most of the NET cases comprise GEP-NETs, the lack of awareness among healthcare professionals and the general public often leads to delayed diagnosis and treatment . GEP-NETs are a heterogeneous group of tumors with diverse clinical presentations, making it difficult to develop standardized treatment protocols. Additionally, challenges in research and development , such as limited funding and resources, hinder advancements in the field, while the complexity of diagnosing GEP-NETs increases the risk of misdiagnosis or delayed diagnosis, resulting in suboptimal treatment outcomes. Moreover, neuroendocrine tumor treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, the NETs market growth may be offset by failures and discontinuation of emerging therapies , unaffordable pricing , market access and reimbursement issues , and a shortage of healthcare specialists . Scope of the Neuroendocrine Tumors Market Report Neuroendocrine Tumors Therapeutic Assessment: Neuroendocrine Tumors current marketed and emerging therapies Neuroendocrine Tumors Market Dynamics: Conjoint Analysis of Emerging Neuroendocrine Tumors Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL’s views, Analyst’s views, Neuroendocrine Tumors Market Access and Reimbursement Discover more about neuroendocrine tumor drugs in development @ Neuroendocrine Tumors Clinical Trials Table of Contents Related Reports Neuroendocrine Tumors Epidemiology Forecast Neuroendocrine Tumors Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted NETs epidemiology in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan. Neuroendocrine Tumors Pipeline Neuroendocrine Tumors Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NETs companies, including RayzeBio, Inc., Seneca Therapeutics, Vyriad, Inc., ADC Therapeutics, Eli Lilly and Company, Biotheus Inc., ImmunityBio, Inc., Chimerix, Merck Sharp & Dohme, Oryzon Genomics S.A., CSPC ZhongQi Pharmaceutical Technology, TaiRx, Inc., Betta Pharmaceuticals, Pfizer, NanOlogy LLC, Cardiff Oncology, Luye Pharma Group, Philogen, Hoffmann-La Roche, Regeneron Pharmaceuticals, among others. Gastroenteropancreatic Neuroendocrine Tumors Market Gastroenteropancreatic Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key GEP-NET companies including Novartis, Ipsen Biopharmaceuticals, Pfizer, ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, Bristol-Myers Squibb, Eisai Limite, Experior S.L., Tarveda Therapeutics, Roche Pharma A, Exelixis, Merck Sharp & Dohme Corp, Recordati Inc, Eli Lilly and Company, Genentech, Inc., Aveo Oncology Pharmaceuticals, Radiomedix, Orano Med, PharmaMar, Bayer, Trio Medicines, among others. Gastroenteropancreatic Neuroendocrine Tumors Pipeline Gastroenteropancreatic Neuroendocrine Tumors Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key GEP-NET companies, including Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation, LLC, Istari Oncology, Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics, Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix, Inc., NanoPharmaceuticals LLC, Erasca, Inc., Oblato, Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences, Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology, Inc., Chimerix, among others. Pancreatic Neuroendocrine Tumors Market Pancreatic Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PNET companies including Novartis Pharmaceuticals, Pfizer, Keyrus Biopharma, Merck Sharp & Dohme LLC, Pfizer, Apices Soluciones S.L., Pharmacyclics LLC, Ipsen, among others. Oncology Conference Coverage Services DelveInsight’s Oncology Conference Coverage Services offer a thorough analysis of outcomes from major events like ASCO, ESMO, ASH, AACR, ASTRO, SOHO, SITC, the European CAR T-cell Meeting, and IASLC. This detailed examination provides businesses with essential insights for competitive intelligence and market trend forecasting, supporting the formulation of future strategies. Other Business Consulting Services Healthcare Competitive Intelligence Healthcare Licensing Services Healthcare Portfolio Management Case Study Learn how the engagement with respected KOLs bolstered the client's reputation as a leader in the pharma industry at KOL Profiling About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn | Facebook | TwitterA stark warning from Booking.com (reported by the BBC) highlights a 900 percent increase in travel scams over the past 18 months, with artificial intelligence playing a key role in promoting such nefarious deeds. In 2023, victims of travel scams in the U.S. lost a total of $265,000 , with nearly 1 in 4 travellers (24 percent) losing $1,000 or more to a single scam. In relation to this, the company AIPRM has compiled a list of the top AI-driven threats travellers should watch out for. Fake airline and hotel booking websites Many criminals create convincing websites that mimic legitimate travel booking platforms. Often advertising irresistible prices for flights and accommodations, these sites lure travellers with offers that seem too good to miss. Fraudsters also often play on urgency, using phrases like “limited-time sale” or “only 1 left” to push consumers into making quick decisions. Once you input your details, scammers can steal your personal and financial information, leaving you with a ticket to nowhere and out of pocket. The best advice is to watch out for suspicious URLs, small spelling errors or anything that feels off about the website’s design or offers. Double-check through official channels and read verified reviews before submitting your personal information. AI chatbots offering fake travel deals AI-powered chatbots can be used by scammers to impersonate customer service representatives, offering huge discounts on flights, hotels, or holiday packages. These bots may ask for sensitive personal information or prompt users to pay upfront for non-existent trips. To avoid falling victim, verify any deals or offers you find online through official travel websites and avoid providing payment information through unfamiliar channels. If something feels too rushed, it’s a red flag. Double-check all details and confirm through official customer service numbers or emails before finalizing any travel booking. Phishing emails and text messages One in five people click on AI-generated phishing emails . Scammers are using AI to craft highly convincing phishing content disguised as legitimate companies. Imagine receiving a text or email claiming your flight is cancelled, and to avoid losing your reservation, you must click a link and enter your payment details immediately. The pressure to act quickly could lead you to inadvertently put your financial information into the hands of fraudsters. AI-generated holiday reviews Fake AI-generated airline reviews have skyrocketed by 189 percent, while Tripadvisor alone flagged a record 2 million reviews as fake on its platform last year. With the rise of AI tools like ChatGPT, scammers can now generate hundreds of seemingly genuine, glowing reviews in minutes, making it harder for travelers to distinguish between real and fraudulent content. Fake travel itineraries and AI-generated images While many travellers nowadays use AI to help plan their trips, scammers are also taking advantage of this technology to create professional-looking itineraries designed to deceive. These fake itineraries often feature attractive holiday packages that promise an unforgettable vacation at an unbeatable price, with AI-generated images used to promote false activities, making everything seem enticing. Dr. Tim Sandle is Digital Journal's Editor-at-Large for science news.Tim specializes in science, technology, environmental, business, and health journalism. He is additionally a practising microbiologist; and an author. He is also interested in history, politics and current affairs.
NEW YORK (AP) — U.S. stocks are climbing Thursday after market superstar Nvidia and another round of companies said they’re making even fatter profits than expected. The S&P 500 was pulling 0.7% higher, as of 2:45 p.m. Eastern time, after flipping between modest gains and losses several times in the morning. Banks, smaller companies and other areas of the stock market that tend do best when the economy is strong helped lead the way, while bitcoin briefly broke above $99,000. Crude oil, meanwhile, continued to rise. The Dow Jones Industrial Average jumped 532 points, or 1.2%, and the Nasdaq composite gained 0.2%. Nvidia's rise of 1.4% was the strongest force pushing the S&P 500 upward after yet again beating analysts’ estimates for profit and revenue. It also gave a forecast for revenue in the current quarter that topped most analysts’ expectations thanks to voracious demand for its chips used in artificial-intelligence technology. Its stock initially sank in afterhours trading Wednesday following the release of the results. Some investors said the market might have been looking for Nvidia's revenue forecast to surpass expectations by even more. But its stock recovered in premarket trading Thursday, and Wedbush analyst Dan Ives said it was another “flawless” profit report provided by Nvidia and CEO Jensen Huang, whom Ives calls “the Godfather of AI.” How Nvidia’s stock performs has tremendous impact because it’s quickly grown into Wall Street’s most valuable company at roughly $3.6 trillion. Its meandering up and down through the day dragged the S&P 500 and other indexes back and forth. The frenzy around AI is sweeping up other stocks, and Snowflake jumped 32.3% after reporting stronger results for the latest quarter than analysts expected. The company, whose platform helps customers get a better view of all their silos of data and use AI, also reported stronger revenue growth than expected. BJ’S Wholesale Club rose 9.1% after likewise delivering a bigger profit than expected. That may help calm worries about how resilient U.S. shoppers can remain, given high prices across the economy and still-high interest rates. A day earlier, Target tumbled after reporting sluggish sales in the latest quarter and giving a dour forecast for the holiday shopping season. It followed Walmart , which gave a much more encouraging outlook. Nearly 90% of the stocks in the S&P 500 were also rising, and the gains were even bigger among smaller companies. The Russell 2000 index of smaller stocks jumped a market-leading 1.9%. Google’s parent company, Alphabet, helped keep indexes in check. It fell 5.5% after U.S. regulators asked a judge to break up the tech giant by forcing it to sell its industry-leading Chrome web browser. In a 23-page document filed late Wednesday, the U.S. Department of Justice called for sweeping punishments that would include restrictions preventing Android from favoring its own search engine. Regulators stopped short of demanding Google sell Android but left the door open to it if the company’s oversight committee continues to see evidence of misconduct. Drops for other Big Tech stocks also weighed on the market, including a 2.4% slide for Amazon. In stock markets abroad, shares of India’s Adani Enterprises plunged 22.6% Thursday after the U.S. charged founder Gautam Adani, 62, in a federal indictment with securities fraud and conspiracy to commit securities and wire fraud. The businessman and one of the world’s richest people is accused of duping investors by concealing that his company’s huge solar energy project on the subcontinent was being facilitated by an alleged bribery scheme. Indexes elsewhere in Asia and Europe were mixed. In the crypto market, bitcoin eclipsed $99,000 for the first time before easing back to roughly $98,250, according to CoinDesk. It’s more than doubled so far this year, and its climb has accelerated since Election Day. President-elect Donald Trump has pledged to make the country “the crypto capital of the planet” and create a “strategic reserve” of bitcoin. Bitcoin also got a boost after Gary Gensler, the chair of the Securities and Exchange Commission who has pushed for more protection for crypto investors, said he would step down in January . Bitcoin and related investments, of course, have a notorious history of big price swings in both directions. MicroStrategy, a company that's been raising cash expressly to buy bitcoin, saw an early gain of 14.6% for its stock on Thursday quickly disappear. It was most recently down 10.7%. In the oil market, a barrel of benchmark U.S. crude rose 2% to bring its gain for the week to 4.8%. Brent crude, the international standard, climbed 1.8%. Oil has been rising amid escalations in the Russia-Ukraine war. In the bond market, Treasury yields edged higher following some mixed reports on the U.S. economy. The yield on the 10-year Treasury rose to 4.43% from 4.41% late Wednesday. One report said fewer U.S. workers applied for unemployment benefits last week in the latest signal that the job market remains solid. Another report, though, said manufacturing in the mid-Atlantic region unexpectedly shrank. Sales of previously occupied homes, meanwhile, strengthened last month by more than expected. AP Business Writers Matt Ott and Yuri Kageyama contributed.
Ninja air fryer with 5,000 five-star reviews now less than £100Big Ten could place four teams in playoff, thanks to IU's rise
MY JOB Name : John Deery Occupation : Communications coach and founder of The Public Speaking Course Background : A trained actor, John Deery has used his communication skills to help people overcome their greatest fear. Death, divorce and moving house are often cited as the greatest trials of life, but, for some, a deserved fourth on that list is the terror of public speaking. Fear of public speaking is a common form of anxiety, and can range from slight nervousness to paralysing fear and panic. As American writer and humorist, Mark Twain observed: “There are two types of public speakers — those who get nervous and those who are liars.” Statistically, over 75% of people suffer from ‘glossophobia’ — a fear of public speaking that manifests as high levels of anxiety and nerves. “Most people are not natural communicators or born public speakers,” explains John Deery. “Many people are fearful, nervous and self-conscious in front of an audience.” He points out the ‘little voice’ in their head is constantly over-thinking: ‘What will they think of me? What if I go blank and forget what I am saying? What happens if I make a mistake?’ That constant voice of fear whispers that people will think you are boring. “That voice says people will laugh at you, that you’re not good enough, that you don’t deserve to be there, that your speech will be a disaster and you will be fully exposed for what you truly are — an imposter.” Those who fail to face their fear of speaking in public are putting themselves at a professional disadvantage, with their incomes likely to be impaired up to 10% and promotion prospects shrinking by 15%, according to research from Columbia University. While research shows the fear of public speaking affects as many as three in four of the population, just 8% of people have taken deliberate measures to overcome it. “Humans are hardwired to be cautious about public speaking. We are social animals who evolved to rely on the group and so to avoid anything that might reduce our standing within it, like speaking out of turn. "The good news is that modern psychology has given us tools to override our programming and while some of the techniques we deploy on The Public Speaking Course are specific to the individual, many can be applied to every public speaking situation.” Mr Deery also cautions a fear of public speaking affects the student population, reducing the likelihood of college graduation by 10%. “I am very big on education and have worked with young people to overcome what would often be shyness at that younger age. I think more needs to be done in schools and universities to address this fear — I’ve seen many people who are frightened to attend a job interview because they don’t know how to behave or respond.” Hiding behind tech or social media and not wanting to physically or vocally engage is a problem that was further exacerbated by covid: “People stay exclusively with email or text in order to shy away from having a conversation. The previous habit of adding a phone number at the end of an email is no longer the case,” he adds. Clear, concise communication and the ability to stand up and speak without fear will help to get your message across, whether that be in a professional work environment or in a personal capacity, is key to overcoming this fear, he says. "I have worked with individuals and companies all over the world — Europe, the USA, Australia, Asia — and it is a fear that goes right across all cultures and ethnicities — a human condition crossing all geographical borders. "Having helped people from all walks of life: graduates starting out, CEOs, business owners, entrepreneurs, doctors, lawyers, teachers and politicians, the terror of standing alone on stage to address large and small numbers is universal." “That fear crosses all boundaries — age, gender, nationality — with the majority in that 35 to 45 age group, generally a time in life when they are starting to advance in their careers and will need to speak at business gatherings or conferences.” He has also worked with a variety of companies and organisations, including PricewaterhouseCoopers, Unilever, BT, Pulsant, HSBC, Apple, Microsoft, NHS, Samsung and KPMG. Fear of public speaking has held back many a career progression, simply because those individuals knew such a promotion would require the ability to address a group or conference — and so they did not take that job opportunity. Mr Deery began his career as an actor working in theatre, television and film. Shortly after leaving the Drama Studio in London, he joined the BBC Radio Drama Repertory Company and appeared in hundreds of radio broadcasts. He has used his presenting skills for many large companies and corporations, including being the main presenter for BT for five years, travelling all over the UK to present their latest technology to boards, business customers and strategic partners. On the back of that work, Mr Deery was asked to develop a one-day course teaching employees to speak and present in public for some of the UK’s leading companies. Thus began his current passion to help people overcome their greatest fear. In terms of helping to improve one’s ability to confront this universal fear, he offers a number of tips. “If you can, always check out where you are speaking beforehand — break the ‘fear’ of the room. Before you begin, take slow, conscious breaths — in through the nose and out through the mouth. Your exhale should last twice as long as your inhale — this will calm you down in any situation.” Staying present and being in the now assists that calm: “Remember you are telling a story — focus on the beginning, middle and end. Make eye contact with your audience where possible, just for a split second, taking in all areas of the room.” Using your body to take up space yields another physical advantage: “Don’t apologise for being there — just be fully present, no matter what happens during your talk. And, if the worst does happen, if you make a mistake or go blank — acknowledge it and move on.” thepublicspeakingcourse.com
Rutgers blows chance for upset after icing Illinois kicker backfires with go-ahead touchdownNone
Menai community rallies around family after loss
- Previous: 22 bet
- Next: bet awards 2024
